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ing as well as renal therapy but to higher general treatment costs
(educated: 4364€; not educated: 2795€). Total number of long
term events prevented for 5.000 patients was 1.810. Results were
most sensitive to improvements in screening rates and the costs
of implementing the program. CONCLUSIONS: Patient educa-
tion reduced late complications and therefore is able to com-
pensate for higher management and treatment costs. Results of
model-based projections demonstrated that the program may be
cost-saving over ten years in an Austrian cost setting.
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OBJECTIVES: The therapy-switching threshold is the blood
glucose level at which a treatment is failing to maintain gly-
caemic control. We assess the impact of a change in therapy-
switching threshold on lifetime cost-effectiveness of treatment
for Type-2 Diabetes in Germany. METHODS: DiDACT is an
established model of Type-2 diabetes, which includes all relevant
costs in taking a sickness funds perspective. German guidelines
recommend a therapy-switching threshold of HbA1c < 7.0%. We
assess an increase to 7.5%, because some patients cannot achieve
a lower threshold in clinical practice. We simulated treatment
histories for cohorts of 1000 obese patients (mean BMI = 34).
Following Metformin monotherapy failure, combination therapy
adding Rosiglitazone (8mg/d) was compared to adding Gliben-
clamide. Costs were discounted at 5% pa. We present both
within-group “absolute” and between-group “incremental”
comparisons. RESULTS: A higher therapy-switching threshold
simultaneously leads to inferior glycaemic control and extended
oral anti-diabetic viability. Deteriorating glycaemic control
increases morbidity and mortality. The absolute effect of weaker
control is smaller in the Rosiglitazone cohort (104 fewer Life-
Years compared to 185 with Glibenclamide). Extending oral
therapy before requiring insulin improves quality-of-life (QOL).
The absolute effect of weaker control is smaller in the Rosigli-
tazone cohort (115 more QALYs compared to 266 with Gliben-
clamide). Superior glycaemic control in the Rosiglitazone cohort
yields incremental Life-Years/QALYs of 188/295 (HbA1c 7.0%)
and 270/143 (HbA1c 7.5%). The higher threshold leads to cost
increases in both cohorts, but reduces incremental costs. The
higher threshold reduces the discounted incremental cost-
effectiveness ratio (ICER) per Life-Year from 27,516€ to 18,345€
and increases the ICER per QALY from 17,523€ to 34,471€.
CONCLUSIONS: When selecting the therapy-switching thresh-
old there is a trade-off between glycaemic control and QOL.
ICERs for proposed care adding Rosiglitazone to Metformin
remain robust to changes in therapy-switching threshold. It is
important to consider both absolute and incremental effects
when changing key model parameters.
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OBJECTIVES: The aim of the study was to assess the costs of
early detection of DM in the Polish population. METHODS: An
analysis of the costs of diagnosis of DM in primary care was
based on an epidemiological study “Screen-Pol 2”, which was
performed in 2003 and 2004, in 119 centres situated through-
out Poland. The detection of DM was carried out according to
ADA and WHO criteria. During the diagnostic process the fol-
lowing tests were performed: random blood capillary glucose
(RBCG), fasting venous plasma concentration (FPG) and oral
glucose tolerance (OGTT). The tests constituted sequential 
steps in a diagnostic pathway used in primary care in Poland.
Third party payer perspective was applied. RESULTS: A total 
of 11,418 undiagnosed patients took part in the study. The
average cost of detection of DM was 23.22€*. The cost of detec-
tion of one case of DM only by RBCG was 20.62€. The cost 
of detection of DM with FPG was 29.43€ and 171.15€ (if
repeated). When OGTT was used the cost of each case of DM
detected reached 390.93€. CONCLUSIONS: The early detection
of DM is a simple and cheap procedure, when introduced as a
screening programme. It is 23 times less expensive than one
year’s treatment of a single case of DM in terms of direct medical
costs and 64 times cheaper in terms of indirect costs. (* 1 Euro
= 4.6 PLN).
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OBJECTIVES: This study was undertaken to quantify the cost
of hospitalization for cardiovascular disease (CVD) in patients
with diabetes over a 5-year period. METHODS: The cohort of
patients with diabetes was identiﬁed in the 1996 Massachusetts
inpatient database using ICD-9 codes and unique patient identi-
ﬁers. Index admission was deﬁned as the ﬁrst admission in 1996
where a diagnosis of diabetes was recorded. Readmissions over
the subsequent 5 years (1996–2000) for ischemic heart (IHD)
disease, cerebrovascular disease, congestive heart failure (CHF)
and other CVD were tallied for each patient. Massachusetts hos-
pital costs, including all accommodations and ancillary services
were estimated from the all payer discharge databases adjusted
to national values, for medical inﬂation, by cost-to-charge ratios,
and are reported in 2002 US dollars. RESULTS: Of the 52,859
patients with diabetes identiﬁed in 1996, one third was admit-
ted for CVD at index, mean age was 68 years and 47% were
male. Case fatality rate during the index admission was 4%. Sub-
sequently, 21,778 (44%) of index admission survivors had at
least one readmission (mean: 2.5, range: 1–33) for a CVD
problem within ﬁve years (57% readmission rate for those
admitted for CVD at index). IHD accounted for 31% of CVD-
related readmissions (mean cost per stay: $12,500), cerebrovas-
cular events for 11% (mean: $8100), CHF for 33% (mean:
$8000) and 25% other CVD (mean: $11,100). Total cumulative
cost for all CVD-related admissions over 5 years was roughly
$670 million. CONCLUSIONS: A substantial proportion of 
hospitalized patients with diabetes can be expected to require
additional hospital-level care for CVD within a 5-year period.
Although the total hospital cost for CVD-related events reported
here is impressive, it is conservative, as it captures only one
aspect of care for CVD in these patients. These results empha-
size the profound economic consequences of cardiovascular com-
plications in patients with diabetes.
